PBLS · Parabilis Medicines, Inc. · Investor Relations
Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.
Recent news
| Date | Headline |
|---|---|
| 2026-09-01 |
Parabilis Medicines to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines (Nasdaq: PBLS), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by unlocking historically undruggable targets, today announced its Chairman, President |
| 2026-08-25 |
Parabilis Medicines Appoints Accomplished Drug Development Leader Craig L. Tendler, M.D., to Board of Directors
CAMBRIDGE, Mass., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines (Nasdaq: PBLS), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by unlocking historically undruggable targets, today announced the appointment of Craig |
| 2026-08-13 |
Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates
Advanced zolucatetide across multiple Wnt/β-catenin-driven diseases, including progress toward planned Phase 3 registrational trial in desmoid tumors Announced strategic research collaboration with Regeneron to develop Antibody-Helicon Conjugates, expanding application of company's proprietary |
| 2026-06-11 |
Parabilis Medicines Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
CAMBRIDGE, Mass., June 11, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines, Inc. (Nasdaq: PBLS) (“Parabilis”), a clinical-stage biopharmaceutical company built to develop transformative medicines addressing some of the most consequential, yet historically undruggable, protein targets driving human |
| 2026-06-10 |
Parabilis Medicines Announces Pricing of Upsized Initial Public Offering
CAMBRIDGE, Mass., June 09, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines, Inc. (Nasdaq: PBLS) (“Parabilis”), a clinical-stage biopharmaceutical company built to develop transformative medicines addressing some of the most consequential, yet historically undruggable, protein targets driving human |
| 2026-05-18 |
Parabilis Medicines Announces Strategic Collaboration with Regeneron Pharmaceuticals to Advance Novel Antibody-Helicon™ Conjugates Across Multiple Therapeutic Areas
The multi-target collaboration combines Parabilis’s novel Helicon™ peptide platform with Regeneron’s industry-leading antibody capabilities Agreement provides for Parabilis to receive $125M from Regeneron, including a $50M upfront payment and a $75M equity commitment, with up to approximately $2.2B |
| 2026-05-07 |
Parabilis Medicines Appoints Biopharmaceutical Finance Leader Alan M. Sebulsky to Board of Directors
CAMBRIDGE, Mass.--( BUSINESS WIRE)-- Parabilis Medicines, a clinical-stage biopharmaceutical company committed to creating extraordinary medicines using its Helicon™ peptide platform to drug historically undruggable targets, today announced the appointment of Alan M. |
| 2026-04-14 |
Parabilis Medicines Expands Executive Leadership Team
Helen Ho, Ph.D. joins Parabilis as Chief Business and Strategy Officer to advance corporate growth strategy and scale business development impact Thomas Kotarakos promoted to Chief Financial Officer to shape financial strategy in support of continued execution across the company’s clinical and |
| 2026-03-11 |
Parabilis Medicines’ Zolucatetide, the First and Only Direct Inhibitor of the Elusive β-catenin:TCF Interaction, Receives FDA Orphan Drug Designation for the Treatment of Desmoid Tumors
Latest milestone underscores accelerating regulatory momentum for the company’s lead investigational Helicon peptide, following FDA Fast Track Designation in desmoid tumors CAMBRIDGE, Mass.--( BUSINESS WIRE)-- Parabilis Medicines, a clinical-stage biopharmaceutical company committed to creating |
| 2026-03-05 |
Parabilis Medicines Reports Early Clinical Evidence that Zolucatetide Reduces Polyp Burden in a Patient with Familial Adenomatous Polyposis
Preliminary clinical data presented at the InSiGHT Biennial Meeting demonstrate significant reductions in duodenal polyposis and the size of the co-existing desmoid tumor in a patient from the ongoing Phase 1/2 trial of zolucatetide CAMBRIDGE, Mass.--( BUSINESS WIRE)-- Parabilis Medicines, a |
| 2026-01-08 |
Parabilis Medicines Announces Oversubscribed $305 Million Financing to Support Ongoing FOG-001 (zolucatetide) Clinical Development Across a Broad Range of Tumors and Advance Pioneering Pipeline and Helicon Platform
Financing co-led by RA Capital Management, Fidelity Management & Research Company, and Janus Henderson Investors CAMBRIDGE, Mass.--( BUSINESS WIRE)-- Parabilis Medicines, a clinical-stage biopharmaceutical company committed to creating extraordinary medicines for people living with cancer using its |
| 2025-11-21 |
Parabilis Medicines Highlights Promising Preliminary Clinical Results in Patients with Adamantinomatous Craniopharyngioma from Ongoing FOG-001 Clinical Trial at SNO 2025
Consistent, significant tumor reductions across all ACP patients mark the second low-complexity Wnt/β-catenin-driven tumor subgroup – alongside desmoid tumors – showing uniform monotherapy activity in multiple patients treated with FOG-001 CAMBRIDGE, Mass.--( BUSINESS WIRE)-- Parabilis Medicines, a |
Past events
| Date | Event | Type |
|---|---|---|
| 2026-09-16 | Morgan Stanley 24th Annual Global Healthcare Conference | Conference |
Source: https://investors.parabilismed.com/stock-information/stock-quote-chart